Core Insights - MaxCyte has signed a strategic platform license agreement with Adicet Bio to utilize its Flow Electroporation® technology and ExPERT™ platform for developing gamma delta T cell therapies [1][2] - Adicet Bio aims to enhance its manufacturing capabilities for allogeneic gamma delta T cell therapies, which are designed for cancer and autoimmune diseases [3][4] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing cell-based therapeutics through its Flow Electroporation® technology and ExPERT™ platform [5] - The company has over 25 years of experience in cell engineering, providing tools and services that support the development of safe and effective treatments [5] Agreement Details - The agreement grants Adicet Bio non-exclusive rights for research, clinical, and commercial use of MaxCyte's technologies, while MaxCyte will receive licensing fees and program-related revenue [2] - MaxCyte's ExPERT™ platform is noted for its high transfection efficiency, cell viability, and scalability, which are essential for developing next-generation cell therapies [4]